ILAE-Asia and Oceania
Starting ketamine for neuroprotection earlier than its current use as an anesthetic/antiepileptic drug late in refractory status epilepticus
We propose that ketamine be started early in the course of human status epilepticus as a neuroprotectant and that it be continued until epileptic discharges are eliminated.
6 March, 2019
The Leadership Development Program is a unique and exclusive opportunity to receive leadership training and network with leaders from around the globe. Session topics include: The Science of Communication, Strategic Planning, Conflict Resolution & Negotiation, Finance, Management Essentials, Assessing and Leveraging Your Leadership Style, Opportunities to Lead within ILAE, and more.
Despite the decrease in the disease burden from 1990 to 2016, epilepsy is still an important cause of disability and mortality. Standardised collection of data on epilepsy in population representative surveys will strengthen the estimates, particularly in countries for which we currently have no or sparse data...
18 February, 2019
Factors predicting cessation of status epilepticus in clinical practice – data from a prospective observational registry (SENSE)
In clinical practice, treatment guidelines were not followed in a substantial proportion of patients. This under‐dosing correlated with lack of cessation of SE. Our data suggest that sufficiently dosed benzodiazepines should be used as first treatment step.
4 February, 2019
Mark your calendar! International Epilepsy Day is a special event which promotes awareness of epilepsy in more than 120 countries each year. Every year on the second Monday of February people join together to celebrate and highlight the problems faced by people with epilepsy, their families and…
14 January, 2019
Subscribe to the ILAE Newsletter
To subscribe, please click on the button below.
Please send me information about ILAE activities and other
information of interest to the epilepsy community